Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Hybio Pharmaceutical Licenses Semaglutide to Vitamedic for Brazil Market

Fineline Cube Jan 11, 2026
Company Deals

Merck in Talks to Acquire Revolution Medicines for $28‑32 Billion in Oncology Push

Fineline Cube Jan 11, 2026
Company Deals

Takeda Licenses Halozyme’s ENHANZE Technology for Vedolizumab in Global Deal

Fineline Cube Jan 11, 2026
Company Deals

Eisai China and Xuanwu Hospital Forge Strategic Cooperation for Drug R&D

Fineline Cube Jan 11, 2026
Company Deals

InduPro Partners with Lilly on $950M Oncology Deal Using Proximity-Guided Platform

Fineline Cube Jan 10, 2026
Policy / Regulatory

NMPA Issues New Rules to Strengthen Pharmaceutical Contract Manufacturing Oversight

Fineline Cube Jan 9, 2026
Company Drug

Genrix Bio’s GR1803 NDA Accepted for BCMA-Targeted Multiple Myeloma Therapy

Fineline Cube Jan 11, 2026
Company Drug

RemeGen’s RC48 Wins Fourth Breakthrough Therapy Designation for Gastric Cancer Combo

Fineline Cube Jan 11, 2026
Company Drug

Xinhua Pharma Wins China Trial Approval for Dual‑Mechanism PAH Drug LXH‑1211

Fineline Cube Sep 29, 2025

Shandong Xinhua Pharmaceutical Co., Ltd. (HKG: 0719) announced that its pulmonary arterial hypertension (PAH) candidate...

Company Drug

Simcere Secures FDA Approval for ADC SIM0609 in Advanced Solid Tumors

Fineline Cube Sep 29, 2025

Simcere Pharmaceutical Group Limited (HKG: 2096) announced that the U.S. Food and Drug Administration (FDA)...

Company Drug

CMS Wins NMPA Green Light for Phase‑3 Trial of MG‑K10 Anti‑IL‑4Rα in Chronic Urticaria

Fineline Cube Sep 29, 2025

China Medical System Holdings Limited (CMS, HKG: 0867) announced that the National Medical Products Administration...

Company Drug

Eisai & Biogen Secure Leqembi China Maintenance Approval

Fineline Cube Sep 29, 2025

Japanese drugmaker Eisai Co., Ltd. (TYO: 4523) and U.S. biopharma Biogen Inc. (NASDAQ: BIIB) announced...

Company Drug

HanX Biopharmaceuticals Secures NMPA Approval for HX044‑HX008 PD‑1 Therapy Combination in Advanced Solid Tumors

Fineline Cube Sep 29, 2025

HanX Biopharmaceuticals (Wuhan) Co., Ltd., a fast‑growing Chinese biotech, announced that the National Medical Products...

Company Deals Drug

Novatim Partners with VRise to Launch KQ‑2003 CAR‑T in India

Fineline Cube Sep 29, 2025

Novatim Immune Therapeutics (Zhejiang) Co., Ltd., a leading Chinese cancer‑immunotherapy firm, announced an exclusive licensing...

Company Drug

CMS Announces Phase 3 Success of Ruxolitinib Cream in Atopic Dermatitis

Fineline Cube Sep 28, 2025

China Medical System Holdings Limited (CMS, HKG: 0867) reported that its Phase 3, randomized, double‑blind, placebo‑controlled...

Company

Merck Names Kai Beckmann as Incoming CEO, Signals Smooth Leadership Transition

Fineline Cube Sep 28, 2025

Merck KGaA (ETR: MRK) announced that Kai Beckmann will assume the roles of Chair of...

Policy / Regulatory

Trump’s New Pharmaceutical Tariffs Will Be Limited to 15% for EU and Japan, White House Says

Fineline Cube Sep 28, 2025

A White House spokesperson clarified that President Donald Trump’s proposed tariffs on imported pharmaceuticals will not...

Company Digital

Beijing Unicet’s QH104A Receives Chinese NMPA Approval for CNS Solid‑Tumor Clinical Trials

Fineline Cube Sep 28, 2025

Beijing Unicet Biotechnology Co., Ltd. announced that its pioneering QH104A—the world’s first B7H3‑targeted, off‑the‑shelf allogeneic...

Company Deals

Wolters Kluwer and the Chinese Academy of Medical Sciences Sign AI‑Driven Medical‑Information Collaboration

Fineline Cube Sep 28, 2025

Wolters Kluwer announced a preliminary collaboration agreement with the Institute of Medical Information of the...

Drug

Leo Pharma Secures First Greater Bay Area Prescription for Anzupgo, a Novel Topical JAK Inhibitor

Fineline Cube Sep 28, 2025

Denmark-based dermatology specialist LEO Pharma A/S announced that the Greater Bay Area’s first prescription of...

Company Deals

Shanghai MicuRx and GenScript’s ProBio Unit Sign Strategic Deal to Accelerate Antibody‑Drug Conjugate (ADC) Development

Fineline Cube Sep 28, 2025

Shanghai MicuRx Pharmaceutical Co., Ltd. (SHA: 688373) and Nanjing ProBio, a subsidiary of GenScript Biotech...

Policy / Regulatory

NHSA Launches 100‑Day Medical‑Insurance Fraud Crackdown Campaign

Fineline Cube Sep 26, 2025

The National Healthcare Security Administration (NHSA) announced a nationwide 100‑Day Action aimed at eradicating illegal...

Company Drug

CSPC Pharma Secures NMPA Approval for Lecanemab Biosimilar, First of Its Kind in China

Fineline Cube Sep 26, 2025

CSPC Pharmaceutical Group Limited (HKG: 1093) announced that the National Medical Products Administration (NMPA) has...

Company Drug

Trump Announces 100% Tariff on Branded Drugs, Exempts U.S.‑Built Pharmaceutical Factories

Fineline Cube Sep 26, 2025

President Donald J. Trump announced via a social‑media post that the United States will impose a 100 % tariff...

Policy / Regulatory

China Unveils National Long‑Term Care Insurance Service Catalog in Pilot Phase

Fineline Cube Sep 26, 2025

The National Healthcare Security Administration (NHSA) released the National Long‑Term Care Insurance Service Catalog (Trial),...

Company Drug

Sichuan Biokin Secures Second Breakthrough Therapy Designation for Izalontamab Brengitecan in Advanced Urothelial Carcinoma

Fineline Cube Sep 26, 2025

China‑based Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced today that the Center for Drug...

Company Drug Policy / Regulatory

Fosun Pharma’s Alovatinib Enters China’s Pediatric Anti‑Tumor SPARK Pilot

Fineline Cube Sep 26, 2025

The Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) announced that...

Company Drug

Eli Lilly Halts Obesity Study of Experimental Drug Bimagrumab for Strategic Reasons

Fineline Cube Sep 26, 2025

Eli Lilly & Co. (NYSE: LLY) announced that it has discontinued a phase I/II trial of...

Posts pagination

1 … 38 39 40 … 606

Recent updates

  • Hybio Pharmaceutical Licenses Semaglutide to Vitamedic for Brazil Market
  • Merck in Talks to Acquire Revolution Medicines for $28‑32 Billion in Oncology Push
  • Genrix Bio’s GR1803 NDA Accepted for BCMA-Targeted Multiple Myeloma Therapy
  • RemeGen’s RC48 Wins Fourth Breakthrough Therapy Designation for Gastric Cancer Combo
  • Merck Initiates Phase 3 Trial for Calderasib + KEYTRUDA QLEX in KRAS G12C NSCLC
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Hybio Pharmaceutical Licenses Semaglutide to Vitamedic for Brazil Market

Company Deals

Merck in Talks to Acquire Revolution Medicines for $28‑32 Billion in Oncology Push

Company Drug

Genrix Bio’s GR1803 NDA Accepted for BCMA-Targeted Multiple Myeloma Therapy

Company Drug

RemeGen’s RC48 Wins Fourth Breakthrough Therapy Designation for Gastric Cancer Combo

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.